PROSTEP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROSTEP (PROSTEP).
Nicotine replacement therapy; binds to nicotinic acetylcholine receptors in the brain, reducing withdrawal symptoms and cravings by providing a controlled dose of nicotine.
| Metabolism | Primarily hepatic via CYP2A6 and CYP2B6; also metabolized by aldehyde oxidase and flavin-containing monooxygenase. |
| Excretion | Primarily renal: approximately 60% as unchanged drug and metabolites. Fecal: <10%. Biliary: negligible. |
| Half-life | Terminal half-life: 24 hours (range 20-28 h). Prolonged in moderate to severe hepatic impairment (up to 40 h). Clinical context: allows once-daily transdermal dosing for smoking cessation. |
| Protein binding | 5-20% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | 2.5 L/kg (range 2.0-3.0 L/kg). High Vd indicates extensive tissue distribution (e.g., lungs, brain, muscle). |
| Bioavailability | Transdermal: approximately 70-80% of the dose delivered systemically (first-pass metabolism avoided). Oral: negligible due to extensive first-pass metabolism. |
| Onset of Action | Transdermal patch: 2-4 hours for plasma nicotine levels to reach 50% of steady state. Clinical effect (reduction of withdrawal symptoms) begins within 2-4 hours of application. |
| Duration of Action | Transdermal patch: steady-state nicotine levels maintained for 24 hours with once-daily application. Clinical effect persists for 24 hours; removal leads to decline over 8-12 hours. |
Initial: 3.5 mg transdermally once daily for 4 weeks, then increase to 7 mg/24 hr; maximum dose 21 mg/24 hr.
| Dosage form | Film, Extended Release |
| Renal impairment | No specific GFR-based adjustments; use with caution in severe renal impairment due to potential nicotine accumulation. |
| Liver impairment | No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to altered nicotine metabolism. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years; not recommended. |
| Geriatric use | No specific dose adjustment required; monitor for adverse effects due to potential age-related pharmacokinetic changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROSTEP (PROSTEP).
| Breastfeeding | Nicotine is excreted into breast milk with an M/P ratio of approximately 2.9. Infant plasma nicotine concentrations can reach 0.07-0.3 ng/mL. Avoid breastfeeding during use or wait 2-3 hours after patch removal. Consider alternative smoking cessation methods. |
| Teratogenic Risk | Pregnancy Category D. First trimester: Nicotine is associated with fetal vasoconstriction and reduced uteroplacental perfusion, potentially causing fetal hypoxia and growth restriction. Second and third trimesters: Continued risk of low birth weight, preterm delivery, and spontaneous abortion. Abrupt discontinuation may cause maternal nicotine withdrawal; however, nicotine replacement carries fetal risks proportional to dose. |
■ FDA Black Box Warning
N/A
| Serious Effects |
["Hypersensitivity to nicotine or any component of the patch","Immediately after myocardial infarction (within 2 weeks)","Severe or worsening angina pectoris","Life-threatening arrhythmias","Active temporomandibular joint disease (for oral formulations; not applicable to patch)"]
| Precautions | ["Risk of nicotine toxicity if used with other nicotine-containing products","Use with caution in patients with cardiovascular disease (e.g., recent MI, serious arrhythmias, unstable angina)","May cause fetal harm; avoid use during pregnancy unless benefit outweighs risk","Surgically impenetrable; remove before MRI","Mucous membrane irritation at application site"] |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth via ultrasonography for growth restriction. Assess maternal blood pressure due to nicotine's vasoconstrictive effects. Evaluate for signs of preterm labor. Monitor maternal smoking cessation progress and withdrawal symptoms. |
| Fertility Effects | Nicotine may impair female fertility by reducing ovarian function and altering tubal motility. In males, nicotine can reduce sperm count, motility, and increase DNA fragmentation. Effects are dose-dependent and potentially reversible upon cessation. |